FDA approves Biogen Idec's Plegridy

FDA approved Plegridy peginterferon beta-1a from Biogen Idec Inc. (NASDAQ:BIIB) to treat relapsing forms of multiple sclerosis (RRMS). The pegylated interferon (IFN) beta-1a is administered subcutaneously every two weeks using the Plegridy Pen autoinjector or a prefilled syringe. The European Commission approved Plegridy for relapsing-remitting MS (RRMS) last month. ...